Fast Growth Calls for a Fresh Look
Streamlining Pharmaceutical R&D OperationsCase Study
Due to rapid growth, a multinational pharmaceutical company was looking to improve efficiency and eliminate layers of redundancy within their R&D operations. ATL was asked to analyze their current R&D functions and overall technical capabilities including quantitative biology, cell culture, and capability dedicated labs. The pharmaceutical company needed help identifying ways to cut costs, improve efficiency and streamline processes — without sacrificing the service and production standards their internal team had come to expect.
Action
ATL took the time to become familiar with and understand the company’s entire R&D operation from their people and systems to their requirements and expectations. As a result, we quickly identified several opportunities. Alongside key stakeholders, we planned and implemented changes that consolidated redundant functions and streamlined processes. We also created a dynamic cross-functional lab platform to support the client’s testing needs across multiple departments and improve their technological capabilities.
Results
Our proactive approach and sincere desire to help enabled our client to:
- Secure immediate cost savings of $1.3 million
- Avoid annual labor and training costs of $480,000
- Realize a 17% increase in methods / assays
- Achieve a 30% reduction in equipment validation timing and a 35% reduction in overall capital expenditures
ATL is pleased to announce our relocation to a newly constructed, state of the art laboratory facility in Cincinnati, OH—marking our first major expansion since joining the Bureau Veritas family. This move represents a significant advancement for our organization and reinforces our commitment to delivering high quality service and technical excellence to our clients.
Our new facility features six additional stability chambers, enabling the launch of an expanded stability program. We have modernized our primary laboratory spaces to support a wide range of bioburden assays, including sterility testing, USP methods, and custom client protocols. In addition, we have enhanced our capabilities in preservative efficacy testing and challenge studies, strengthening the breadth of services we can provide.
This move is more than a change of address—it’s a strategic investment in innovation, enhanced capability, and the future of ATL.